Capula Management Ltd Takes Position in Biogen Inc. $BIIB

Institutional investor acquires new stake in biotech company Biogen.

Mar. 15, 2026 at 11:04am

Got story updates? Submit your updates here. ›

Capula Management Ltd, an institutional investor, acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the 3rd quarter, according to the company's recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,208 shares of the biotechnology company's stock, valued at approximately $1,430,000.

Why it matters

This investment by Capula Management Ltd in Biogen suggests the institutional investor sees potential in the biotech company's future prospects. Biogen is a major player in the pharmaceutical industry, particularly in the areas of multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease treatments.

The details

In addition to Capula Management Ltd's new position, other institutional investors have also recently modified their holdings of Biogen. Convergence Investment Partners LLC, Caprock Group LLC, Pitcairn Co., and Fluent Financial LLC all purchased new stakes or increased their existing positions in Biogen during the 3rd quarter.

  • Capula Management Ltd acquired the new position in Biogen in the 3rd quarter of 2026.
  • Biogen's stock opened at $181.55 on Friday, March 15, 2026.

The players

Capula Management Ltd

An institutional investor that acquired a new position in shares of Biogen Inc.

Biogen Inc.

A multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases, headquartered in Cambridge, Massachusetts.

Got photos? Submit your photos here. ›

The takeaway

Biogen's stock continues to attract interest from institutional investors like Capula Management Ltd, suggesting confidence in the company's ability to develop innovative treatments for neurological conditions and maintain its position as a leader in the biotech industry.